公开(公告)号：US20150238560A1

公开(公告)日：2015-08-27

申请号：US14549096

申请日：2014-11-20

Applicant: Tarix Pharmaceuticals Ltd.

Inventor： Richard Franklin

IPC: A61K38/08

CPC classification number: A61K38/085

Abstract: The present invention provides, among other things, method of treating stroke including a step of administering an angiotensin (1-7) peptide to a subject suffering from a stroke, approximately 24 hours after the stroke. In some embodiments, treatment begins more than 24 hours after the stroke. In some embodiments, administration of an angiotensin (1-7) peptide results in a reduction in the intensity, severity, duration, and/or frequency of at least one symptom or feature of the one or more complications of stroke.

Abstract translation: 本发明尤其提供了治疗中风的方法，包括在中风后约24小时向患有卒中的受试者施用血管紧张素（1-7）肽的步骤。 在一些实施方案中，治疗在卒中后超过24小时开始。 在一些实施方案中，施用血管紧张素（1-7）肽导致中风的一种或多种并发症的至少一种症状或特征的强度，严重程度，持续时间和/或频率的降低。

公开(公告)号：US09107870B2

公开(公告)日：2015-08-18

申请号：US14506489

申请日：2014-10-03

Applicant: TARIX PHARMACEUTICALS LTD

Inventor： Richard Franklin

IPC: A61K38/08 ,  A61K31/4178 ,  A61K45/06

CPC classification number: A61K38/085 ,  A61K31/4178 ,  A61K45/06 ,  A61K47/60 ,  A61K47/64 ,  A61K2300/00

Abstract: The present invention provides, among other things, methods of treating Marfan Syndrome and/or a Marfan-related disorder including administering to a subject suffering from or susceptible to Marfan Syndrome and/or a Marfan-related disorder an angiotensin (1-7) peptide. In some embodiments, the angiotensin (1-7) peptide is administered at an effective dose periodically at an administration interval such that at least one symptom or feature of Marfan Syndrome and/or a Marfan-related disorder is reduced in intensity, severity, duration, or frequency or has delayed in onset.

Abstract translation: 本发明尤其提供了治疗马凡氏综合征和/或马凡相关病症的方法，包括对患有或易患马凡氏综合征和/或马凡氏病的受试者施用血管紧张素（1-7）肽 。 在一些实施方案中，血管紧张素（1-7）肽以有效剂量以给药间隔周期性地施用，使得Marfan综合征和/或Marfan相关病症的至少一种症状或特征降低强度，严重程度，持续时间 ，或发生频率或迟发。